Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Abiomend-XPlus
- Development stage
- Unknown
- Lead developer
- Halo Biologics
- Administration
- Topical, Surgical Implant
01
Overview
Abiomend-XPlus is an advanced human cellular and tissue-based product (HCT/P) developed and distributed by Halo Biologics. It is composed of dehydrated human amniotic membrane (dHAM) and is specifically engineered for use as a biological scaffold in wound care and surgical applications. The XPlus designation refers to a multi-layered configuration that provides enhanced structural integrity and a higher concentration of endogenous regenerative components compared to standard single-layer membranes. Abiomend-XPlus functions by providing a natural extracellular matrix (ECM) that facilitates cellular migration, adhesion, and proliferation. It also serves as a reservoir for essential growth factors, cytokines, and proteins that help modulate the inflammatory response and promote accelerated tissue repair. It is primarily utilized in the management of chronic wounds, such as diabetic foot ulcers and venous leg ulcers, as well as in orthopedic, spinal, and plastic reconstructive surgeries.
- Brand names
- Abiomend-XPlus
- Other names
- Abiomend XPlus
02
Targets
PDGF (Platelet-derived Growth Factor family)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on Abiomend-XPlus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abiomend-XPlus.